New partnerships strengthen CVS Health's Boston ties

CVS Health will partner with startup accelerator MassChallenge and digital health venture fund Rock Health to drive innovation for connected health solutions.

CVS Health announced its Digital Innovation Lab in June.

“We know that some of the best digital health innovations are already being developed, so we’ve made partnering a key part of our digital efforts,” said Brian Tilzer, CVS Health's senior vice president and chief digital officer, in a release. “We have broad scale and resources; MassChallenge offers a competitive startup accelerator program and Rock Health has an impressive portfolio of market-leading companies. By working collaboratively with each, we can rapidly design and test new ideas-–ultimately bringing solutions to our customers that will dramatically impact the way they manage their health.”

As part of its digital strategy, CVS Health is focusing on innovation areas including mobile, personalization, connected health and digital therapeutics.

The relationship with MassChallenge will help CVS Health further its connections in the Boston technology community, according to the release. MassChallenge runs startup accelerators in Boston, Israel and the U.K., designed to connect high-impact startups with the resources they need to launch and succeed. Through the partnership, high-potential startups will have access to CVS Health’s resources to help facilitate the development of the next generation of customer-centric products.

California-based Rock Health is the first venture fund dedicated to digital health. The two organizations plan to share each other's resources to "deepen relationships with key stakeholders that share the goal of solving today’s healthcare challenges."

 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.